SCHEMBL513700

SCHEMBL513700

Cn1nc(CBr)cc1-c1cccs1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.36
KDM4E B2RXH2 6/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
FYN P06241 3/20 0.36
HSD17B10 Q99714 3/20 0.36
GAA P10253 3/20 0.36
TP53 P04637 1/20 0.36
SLC16A3 O15427 1/20 0.35
SLC16A1 P53985 1/20 0.35
MCTS1 Q9ULC4 1/20 0.35
ADORA1 P30542 1/20 0.35
NTRK3 Q16288 1/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
GRK5 P34947 1/20 0.34
HPGD P15428 3/20 0.34
TSHR P16473 2/20 0.34
GLA P06280 1/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27890781 0.84 SLC16A3 (0.38) ALDH1A1KDM4EL3MBTL1FYNHSD17B10
SCHEMBL513361 0.84 FYN (0.41) ALDH1A1KDM4EL3MBTL1FYNHSD17B10
SCHEMBL2050232 0.83 SREBF2 (0.43) ALDH1A1KDM4EL3MBTL1FYNHSD17B10
SCHEMBL14232845 0.77 NPC1 (0.41) ALDH1A1KDM4EL3MBTL1FYNHSD17B10
SCHEMBL435263 0.77 ALDH1A1 (0.49) ALDH1A1KDM4EL3MBTL1FYNHSD17B10
SCHEMBL513268 0.74 SLC16A3 (0.42) ALDH1A1KDM4EL3MBTL1FYNGAA
SCHEMBL4548028 0.72 KDM4E (0.58) ALDH1A1KDM4EL3MBTL1HSD17B10GAA
SCHEMBL4548038 0.72 KDM4E (0.51) ALDH1A1KDM4EL3MBTL1HSD17B10GAA
SCHEMBL570365 0.71 PIM1 (0.54) ALDH1A1KDM4EL3MBTL1HSD17B10GAA
SCHEMBL27818920 0.70 FYN (0.37) ALDH1A1KDM4EL3MBTL1FYNGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2477981-A1 HETEROCYCLIC MGLU5 ANTAGONISTS Recordati Ireland Limited (IE) 2012-07-25 EP disclosed
US-20120028931-A1 HETEROCYCLIC M-GLU5 ANTAGONISTS RECORDATI IRELAND LIMITED (IE) 2012-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028931-A1 HETEROCYCLIC M-GLU5 ANTAGONISTS OPRM1, GRM5, OPRD1 ALDH1A1 2610/4885KDM4E 3490/4885L3MBTL1 1294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.